WEBULL
News
CDNA
19.63
+2.77%
0.53
Analysts Have Conflicting Sentiments on These Healthcare Companies: CareDx (CDNA), Neurocrine (NBIX) and Viking Therapeutics (VKTX)
TipRanks · 2d ago
CareDx Unveils Clinical Validation Results for AlloHeme AI-Powered Leukemia Relapse Test
Reuters · 2d ago
CAREDX ANNOUNCES CLINICAL VALIDATION RESULTS FOR ALLOHEME™, THE FIRST AI‑POWERED NGS SURVEILLANCE SOLUTION FOR AML AND MDS POST‑CELL THERAPY
Reuters · 2d ago
CareDx Inc. to Report Fourth Quarter and Full Year 2025 Financial Results
Reuters · 3d ago
Weekly Report: what happened at CDNA last week (0202-0206)?
Weekly Report · 5d ago
Analysts Conflicted on These Healthcare Names: CareDx (CDNA) and DaVita (DVA)
TipRanks · 02/03 14:40
CareDx kündigt Präsentation klinischer Validierungsdaten zum AlloHeme-Test zur Rückfallüberwachung bei Blutkrebspatienten an
Reuters · 02/03 12:05
CareDx to Present AlloHeme Pivotal Clinical Validation Data for Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
Reuters · 02/03 12:05
Weekly Report: what happened at CDNA last week (0126-0130)?
Weekly Report · 02/02 09:19
CareDx to Participate in BTIG 13th Annual MedTech Conference
Reuters · 01/27 21:06
Weekly Report: what happened at CDNA last week (0119-0123)?
Weekly Report · 01/26 09:19
CareDx Inc. President and CEO John Walter Hanna Jr. Reports Disposal of Common Shares
Reuters · 01/23 22:58
Analysts Conflicted on These Healthcare Names: Ufp Technologies (UFPT), Eledon Pharmaceuticals (ELDN) and CareDx (CDNA)
TipRanks · 01/23 14:50
CareDx President and CEO John Walter Hanna, Jr. Reports Sale of Common Shares
Reuters · 01/20 22:31
Weekly Report: what happened at CDNA last week (0112-0116)?
Weekly Report · 01/19 09:20
NTRA & NVDA Partner to Improve AI Models for Precision Medicine
NASDAQ · 01/13 15:45
Implied Volatility Surging for CareDx Stock Options
NASDAQ · 01/13 13:30
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Vertex Pharmaceuticals (VRTX) and CareDx (CDNA)
TipRanks · 01/13 03:40
CareDx: Solid Near-Term Beat but LCD Overhang and Reimbursement Uncertainty Justify Hold Rating
TipRanks · 01/13 02:56
CareDx Up Over 17%, on Pace for Largest Percent Increase Since August 2024 -- Data Talk
Dow Jones · 01/12 18:34
More
Webull provides a variety of real-time CDNA stock news. You can receive the latest news about Caredx through multiple platforms. This information may help you make smarter investment decisions.
About CDNA
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.